A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
In a paper published in Alzheimer’s and Dementia, a team of researchers called for more prospective studies that will look into the impact COVID-19 has on brain functioning, given the disease has been frequently associated with neurologic symptoms such as seizures and psychosis.
Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals Limited announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.
An FDA advisory panel voted against approving Alkermes Plc’s depression treatment ALKS 5461 in patients with an inadequate response to standard antidepressant therapies.
A moderate-intensity walking regimen may reduce symptoms of mild cognitive impairment that are linked to poor blood vessel health in the brain, a small study suggests.
Intra-Cellular Therapies Inc said a higher dose of its lead drug was found to be effective in reducing the severity of schizophrenia symptoms in a late-stage study, sending its shares up more than 50 percent in premarket trading. Patients treated with 60 mg of the drug, ITI-007, showed improvement over placebo. The 40 mg dosage, […]
The U.S. Food and Drug Administration (FDA) advised Waltham, Mass.-based FORUM Pharmaceuticals to halt its clinical trials of encenicline for Alzheimer’s disease yesterday. The FDA cited a small number of serious gastrointestinal (GI) side effects in the studies. As a result, FORUM halted the trial, discontinuing the medication and no new patients will be recruited […]
(Reuters Health) – Older adults with low vitamin D levels – and that accounts for most of them – may lose their memories and thinking abilities faster than those with normal vitamin D levels, researchers say. “We were not particularly surprised by our findings because there is a recent and growing literature on the associations […]
A new study published in the journal Neurology shows that Type 2 diabetes triggers a significant reduction in cognitive ability within just a two-year period. The main culprits appear to be increased tissue inflammation and decreased blood flow to the brain. Researchers conducted several tests on 65 participants (average age 66) at the beginning of a […]